Elan Corp. of Athlone, Ireland named Donal J. Geaney presidentand chief operating officer. He is currently chief financialofficer.
Geaney, along with Kenneth W.H. McVey and Seamus Mulligan,was also named to the newly created office of the chairman.McVey is executive vice president for business planning anddevelopment and Mulligan is executive vice president forpharmaceutical operations worldwide.
Sepracor Inc. of Marlborough, Mass., named Gunnar Aberg vicepresident of research and development for the company'spharmaceutical division. He was executive director ofpharmacology for Bristol-Myers Squibb Co.
Texas Biotechnology Corp. of Houston named Hans Mark to itsboard of directors. He retired on Aug. 31 as chancellor of theUniversity of Texas system and now serves as professor ofaeronautical engineering and engineering mechanics at theAustin campus of the university.
Genetic Therapy Inc. of Gaithersburg, Mass., named Robert C.Riley to the new position of senior vice president for businessplanning and development. He was senior director of businessdevelopment and planning for Bristol-Myers Squibb.
Allelix Biopharmaceuticals Inc. of Toronto named Suman Rakhitdirector of medicinal chemistry. He had been director ofchemistry for Bio-Mega Inc. in Montreal.
Roberts Pharmaceutical Corp. of Eatontown, N.J., named RobertW. Loy chief operating officer. He had been vice president forinternational sales and marketing for Hollister Inc.
(c) 1997 American Health Consultants. All rights reserved.